HowShorted

How shorted is Oruka Therapeutics, Inc.?

More shorted than 86% of the 2,877 ranked US companies

12.16%
of shares outstanding reported short · settlement date 31 Jul 2026
vs previous report
−2.49
5 reports (~10 weeks)
+1.79
Aggregate net short position time series for Oruka Therapeutics, Inc.
Embed this chart

Paste this snippet to embed the interactive chart. It updates with each FINRA report and keeps the source attribution. Preview

Cite this page

History

Settlement dateShort %Change
31 Jul 202612.16%−2.49
15 Jul 202614.65%−0.54
30 Jun 202615.19%+3.75
15 Jun 202611.44%+0.87
29 May 202610.57%+0.20
15 May 202610.37%−1.22
30 Apr 202611.59%+0.15
15 Apr 202611.44%+2.10
31 Mar 20269.34%+1.81
13 Mar 20267.53%−1.70
27 Feb 20269.23%+0.84
13 Feb 20268.39%−1.75
30 Jan 202610.14%−0.69
15 Jan 202610.83%−4.92
31 Dec 202515.75%+3.71
15 Dec 202512.04%+0.68
28 Nov 202511.36%+0.52
14 Nov 202510.84%+0.08
31 Oct 202510.76%+0.09
15 Oct 202510.67%+1.02
30 Sep 20259.65%+1.46
15 Sep 20258.19%−0.35
29 Aug 20258.54%−2.95
15 Aug 202511.49%+2.52
31 Jul 20258.97%–

Frequently asked questions

How shorted is Oruka Therapeutics, Inc. right now?
12.16% of Oruka Therapeutics, Inc.'s (ORKA) shares outstanding were reported short for settlement date 31 Jul 2026, per FINRA's consolidated short interest report.
What does this number include?
FINRA member firms must report their short positions in all US equities twice a month; FINRA consolidates them per security. We divide that official share count by the company's shares outstanding from its SEC filings. This is the regulatory figure, not a daily estimate.
Why does it only update twice a month?
US short interest is reported for settlement on the 15th and the last business day of each month, and FINRA publishes the consolidated figures about nine business days later. That cadence is set by regulation; no daily official figure exists.
Which funds are short?
US public short interest is aggregate-only: individual short sellers are not named. Only some EU markets publish named positions.